MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 09-10-2025
Anixa Biosciences Interest Expense 2011-2026 | ANIX
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Anixa Biosciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | 500 K | 520 K | 452 K | 1.26 M | 1.11 M | 7.66 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.26 M | 7.66 K | 642 K |
Quarterly Interest Expense Anixa Biosciences
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.27 K | - | - | 53.8 K | 18.4 K | - | - | - | - | - | 195 K | 443 K | 71.7 K | 176 K | 124 K | 383 K | 132 K | 127 K | 109 K | 334 K | 116 K | 109 K | 379 K | 1.08 M | 281 K | 422 K | 22.2 K | 983 K | 125 K | 835 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.08 M | 7.27 K | 284 K |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M |  USA |
 |
Burning Rock Biotech Limited
BNR
|
1.54 M | $ 22.9 | 19.89 % | $ 246 M |  China |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
BioNano Genomics
BNGO
|
-10.1 M | $ 1.6 | -0.62 % | $ 2.03 M | USA |
 |
Co-Diagnostics
CODX
|
106 K | $ 6.05 | 6.14 % | $ 178 M | USA |
 |
Castle Biosciences
CSTL
|
1 K | $ 40.8 | 1.83 % | $ 1.13 B | USA |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
Danaher Corporation
DHR
|
-56 M | $ 234.89 | -0.73 % | $ 172 B | USA |
 |
DarioHealth Corp.
DRIO
|
-31 K | $ 12.11 | -10.18 % | $ 344 M |  Israel |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M | China |
 |
DexCom
DXCM
|
20.3 M | $ 70.15 | 0.37 % | $ 27.1 B | USA |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | $ 101.62 | -0.03 % | $ 18.8 B | USA |
 |
CareDx, Inc
CDNA
|
1.34 M | $ 18.99 | 0.96 % | $ 1.02 B | USA |
 |
Fulgent Genetics
FLGT
|
561 K | $ 27.97 | 7.62 % | $ 846 M | USA |
 |
Celcuity
CELC
|
2.11 M | $ 109.72 | 4.47 % | $ 4.33 B | USA |
 |
Guardant Health
GH
|
-42.6 M | $ 110.12 | -1.97 % | $ 13.5 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
288 M | $ 29.05 | 1.22 % | $ 20 B |  Niderland |
 |
Aspira Women's Health
AWH
|
106 K | - | -6.19 % | $ 10.5 M | USA |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
IQVIA Holdings
IQV
|
670 M | $ 244.09 | 1.5 % | $ 44.3 B | USA |
 |
Illumina
ILMN
|
-292 M | $ 151.07 | 2.65 % | $ 24 B | USA |
 |
Charles River Laboratories International
CRL
|
-16.5 M | $ 216.28 | - | $ 11.1 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
30 M | $ 178.22 | -1.22 % | $ 19.8 B | USA |
|
Biodesix
BDSX
|
8.26 M | $ 5.86 | -2.82 % | $ 760 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
208 M | $ 253.83 | -2.49 % | $ 21.3 B | USA |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | Israel |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 202.64 | 0.58 % | $ 16.7 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
29.8 M | $ 710.27 | 0.49 % | $ 58.6 B | USA |
 |
Lantheus Holdings
LNTH
|
37.2 M | $ 69.22 | -0.66 % | $ 4.79 B | USA |
 |
Agilent Technologies
A
|
81 M | $ 147.47 | -0.1 % | $ 44.8 B | USA |
 |
Biomerica
BMRA
|
367 | $ 2.78 | 5.41 % | $ 6.39 M | USA |
 |
Bioventus
BVS
|
1.29 M | $ 7.56 | -1.18 % | $ 474 M | USA |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M | Israel |
 |
QIAGEN N.V.
QGEN
|
-739 K | $ 47.23 | 0.32 % | $ 10.5 B | Niderland |
 |
Mettler-Toledo International
MTD
|
74.6 M | $ 1 462.87 | -1.54 % | $ 31 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
1.1 M | $ 6.7 | 2.68 % | $ 607 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-691 K | $ 4.51 | -1.96 % | $ 2.42 M | USA |
 |
NeoGenomics
NEO
|
-379 K | $ 12.69 | -0.78 % | $ 1.61 B | USA |